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Background: It is unknownwhy patients with autoantibodies against complement factorH (CFH) lack homologousCFHR1
protein.
Results: The autoantibody epitope on CFH was identified, and the structure of the corresponding part of CFHR1 was solved.
Conclusion: The autoantigenic epitope of CFH and its homologous site in CFHR1 are structurally different.
Significance:A plausible explanation for formation of autoantibodies due to CFHR1 deficiency in autoimmune atypical hemo-
lytic uremic syndrome was obtained.
Atypical hemolytic uremic syndrome (aHUS) is characterized
by complement attack against host cells due to mutations in
complement proteins or autoantibodies against complement
factor H (CFH). It is unknownwhy nearly all patients with auto-
immune aHUS lack CFHR1 (CFH-related protein-1). These
patients have autoantibodies against CFH domains 19 and 20
(CFH19–20), which are nearly identical to CFHR1 domains 4 and
5 (CFHR14–5). Here, binding site mapping of autoantibodies
from 17 patients usingmutant CFH19–20 constructs revealed an
autoantibody epitope cluster within a loop on domain 20, next
to the two buried residues that are different in CFH19–20 and
CFHR14–5. The crystal structure of CFHR14–5 revealed a differ-
ence in conformation of the autoantigenic loop in the C-termi-
nal domains of CFH and CFHR1, explaining the variation
in binding of autoantibodies from some aHUS patients to
CFH19–20 and CFHR14–5. The autoantigenic loop on CFH
seems to be generally flexible, as its conformation in previously
published structures of CFH19–20 bound to the microbial pro-
tein OspE and a sialic acid glycan is somewhat altered. Cumula-
tively, our data suggest that association of CFHR1 deficiency
with autoimmune aHUS could be due to the structural differ-
ence between CFHR1 and the autoantigenic CFH epitope, sug-
gesting a novel explanation for CFHR1 deficiency in the patho-
genesis of autoimmune aHUS.
Atypical hemolytic uremic syndrome (aHUS)3 is a rare and
often fatal systemic disease characterized by hemolytic anemia,
thrombocytopenia, microvascular thrombosis, and kidney fail-
ure (1). It is associated with dysregulation of complement acti-
vation via mutations, polymorphisms, or rearrangements in
genes coding for various complement proteins (2). The muta-
tions are found mainly in the gene coding for complement fac-
tor H (CFH) (3, 4), which mediates elimination of the central
complement activation component C3b. We and others (5–8)
have shown howmutations in CFH domains 19 and 20 (CFH19–20)
cause impaired regulation of C3b on host cells, leading to com-
plement attack against red blood cells, platelets, and endothelial
cells as seen clinically in aHUS. However, some aHUS cases are
caused by autoantibodies against CFH (CFH-AAs). These anti-
bodies have been identified in 5–11% of aHUS patients in dif-
ferent cohorts (9–13), but even 56% of 246 HUS patients have
been reported with CFH-AAs in India (14). In nearly all of the
cases, the patients have autoantibodies against the C terminus
of CFH, although usually in addition to such antibodies, some
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patients have autoantibodies against other parts of CFH as well
(10, 15). Patients with the autoimmune form of aHUS nearly
always lack certain CFH-related proteins, primarily CFHR1
(CFH-related protein-1) (10, 16).
CFH and CFHR proteins are encoded by adjacent genes and
formaprotein family (Fig. 1) (17). CFHRproteins are composed
of four to nine complement control protein domains, also
called short consensus repeats, and the two most C-terminal
domains have relatively high sequence homologies to theC-ter-
minal domains of CFH (Fig. 1) (17). There are only two residues
that are different in the last two C-terminal domains of CFH
and CFHR1 (domains 19–20 and 4–5, respectively). The func-
tional importance of theseminor differences is obvious because
the hybrid CFH/CFHR1 genes producing fusion proteins
CFH1–18/CFHR14–5 and CFHR11–3/CFH19–20 have been found in
aHUS patients in the absence of other mutants or CFH-AAs (4,
18–20). Domains 19 and 20 of CFH are responsible for direct-
ing its complement regulatory activity to cell and extracellular
matrix surfaces by binding simultaneously to both C3b and
negatively charged glycosaminoglycans or sialic acid glycans on
the surfaces (6, 21, 22). The autoantibodies of nearly all patients
with autoimmune aHUS recognize the C terminus of CFH, and
inhibit the physiological CFH-mediated protection of host cells
from complement attack (10, 11, 13, 15, 23).
More than 90% of patients with CFH-AAs lack CFHR1 and
CFHR3, resulting from a homozygous deletion of the genomic
region containing both of them (10, 12, 13, 16). Some patients
have other rarer genetic alterations, including a homozygous
CFHR1/CFHR4A deletion (12), a combination of heterozygous
CFHR1/CFHR3 and CFHR1/CFHR4A deletions (12, 13), or a
combined heterozygous CFHR1/CFHR3 deletion in the pres-
ence of a missense mutation in CFHR1 (12). The common fea-
ture in these genetic alterations is a deficiency of CFHR1 (24,
25). However, CFH-AAs have also been described, although
rarely, in patients with two normal copies of CFHR1 and
CFHR3 but mutations in CFH, CFI, CD46, or C3 genes (12, 13).
CFH-AAs often cross-react with CFHR1 (13, 15, 26), but the
exact location of the autoantibody site on CFHR1 has not been
determined. On the basis of inhibition of autoantibody binding
to CFHR1 by mAb C18 (26) and the sequence homology to the
C terminus of CFH, it is likely, however, that the autoantibody-
binding site is within the last two domains of CFHR1, i.e. far
away from its N-terminal dimerization site (27).
To date, the reason for the association between CFH-AAs
and CFHR1 deficiency has been unknown. In this study, we
aimed to solve why a deficiency of one molecule (CFHR1) pre-
disposes to autoimmunity against another, highly homologous
molecule (CFH) in aHUS. We mapped the binding sites of
CFH-AAs within CFH19–20 and compared the CFH-AA-bind-
ing sites with the previously reported ligand-binding sites on
CFH19–20. Because the autoantibody epitopes formed a cluster
next to the residues that are different in the two C-terminal
domains of CFH and CFHR1, we decided to solve and analyze
the structure of CFHR14–5 and to study the potential differ-
ences in antigenicity of those two molecules. We found struc-
tural differences in the autoantibody-binding site of CFH
domain 20 and the corresponding homologous site of CFHR1
domain 5. Based on these data, a novel model is proposed, sug-
gesting how immunization against CFH domain 20 could be
linked to CFHR1 deficiency.
EXPERIMENTAL PROCEDURES
Proteins—Cloning, expression, and purification of WT CFH19–20
and mutant proteins with the 14 single-point mutations have
been described previously (5, 7, 28). Proper folding of the con-
structs was verified for three mutants (Q1139A, R1203A,
D1119G/Q1139A) by solving the structures by x-ray crystallog-
raphy (6, 28, 29) and for five mutants (R1182A, W1183L,
K1188A, E1198A, and R1206A) by circular dichroism (30).
CFHR14–5 was generated by site-directed mutagenesis of
CFH19–20-encoding DNA in the pPICZB vector (Invitrogen).
The primer used to introduce the S1191L and V1197Amutations
wasCAGAAGCTTTATTTGAGAACATCAGGTGAAGAA
GCT TTT GTG. The mutations were confirmed by sequencing
before expression of CFHR14–5 in Pichia pastoris (strain X-33)
using 1%methanol induction as described previously (7).
Recombinant CFHR1, CFH1–7, CFH8–14, CFH15–20, and
CFHR4B were generated as described previously (31, 32). CFH
was purchased fromMerck. mAbC18 (33) was purchased from
Enzo Life Sciences (Lörrach, Germany).
Patients and Blood Samples—The studies were approved by
the Research Ethics Committee of the Medical Faculty of
Friedrich Schiller University Jena and were performed in
accordance with the Declaration of Helsinki. Patients with
aHUSwere screened for CFH-AAs using ELISA as described (9,
11). All patients lacked the CFHR1 and CFHR3 genes and pro-
teins except for patient 2,whohad two copies of both genes, and
patient 10, who carried a homozygousCFHR1 deletion and was
heterozygous for CFHR3. Three of the patients (patients 3, 7,
and 8) have been described previously (23). The characteristics
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FIGURE 1. Schematic illustration indicating the amino acid sequence
identity of CFH to other members of the CFH family. Each CFHR or CFHL
domain is shown below the domain of CFH towhich it has the highest amino
acid sequence identity. For sequence identities of 32–49%, the domains are
shown inwhite; for 57–84% identity, in light gray; and for 85–100% identity, in
dark gray. The identity betweendomains 3–5ofCFHR1anddomains 18–20of
CFH is indicated as a percentage. The asterisk indicates that the sequence
identity of domain 3 in the basic isoform of CFHR1 to domain 18 in CFH is
100%, whereas that of the acidic isoform is 95% (12). CFHL-1 (CFH-like mole-
cule-1) is an alternatively spliced transcript from the CFH gene with four
unique residues following domain 7.
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of the sera containing CFH-AAs from the 17 patients are sum-
marized in Table 1.
Microtiter Plate Assays—WT or mutant CFH19–20 proteins
(5 g/ml) were coated onto Nunc MaxiSorp plates (Thermo
Scientific). Binding of patient sera (1:50–1:200 depending on
the antibody titer) was analyzed as described (11). Binding of
mAb C18 (5 g/ml) was detected using peroxidase-conjugated
swine anti-mouse IgG.
Binding of patient CFH-AAs (sera diluted 1:100) to CFH, its
recombinant fragments, CFHR1, andCFHR14–5was compared
CFH19-20 
mutants 
Patients 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
D1119G  
Q1139A   
W1157L 
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L1189R                  
E1198A               
R1203A 
R1206A 
R1210A  
R1215Q 
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C E D 
FIGURE2.Mappingof theCFH-AA-binding regiononCFH19–20.A, bindingof IgG from17aHUSpatients andmAbC18 to14CFH19–20 constructswith various
single-point mutations in relation to binding toWT CFH19–20. Error bars indicate S.E., and the level of WT binding is indicated by dotted lines. B, comparison of
the autoantibody-binding epitopes by identification of themutations that impaired binding of patient IgG by at least 30% (indicated by2). C, locations of the
residues involved in binding of autoantibodies to CFH19–20 as indicated in dark gray and annotated on a previously published structure of CFH19–20 (Protein
Data Bank code 2G7I) (7). The location of Trp-1183 is indicated by stripes. D and E, for comparison, the locations of residues involved in binding of CFH19–20 to
heparin (5, 40) (D) and in the commonmicrobe-binding site on CFH19–20 (30) (E) are indicated in dark gray.
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as described above using 250 nM immobilized recombinant
proteins, plasma-purified CFH (65 nM), or recombinant
CFHR4B and albumin as negative controls. Relative binding
was calculated from representative data sets performed in trip-
licates. Equal binding of anti-CFH polyclonal antiserum and
negligible binding of anti-IgG to the CFH19–20 mutants were
confirmed by ELISA.
The assay comparing the binding avidity of CFH19–20 and
CFHR14–5 with purified IgG from patient 11 was done after
coating CFH19–20 (10 g/ml) onto Nunc MaxiSorp plates.
After blocking (0.05% Tween 20 in PBS) for 120 min and wash-
ing (0.02% Tween 20 in PBS), 40 l of patient IgG (3.8 g/ml)
and CFH19–20, CFHR14–5, or CFH5–7 were added in different
dilutions and incubated for 120 min at 37 °C, followed by mea-
suring IgG binding as described (11). The experiment was per-
formed three times in triplicates, and the background sub-
tracted datawere normalized using the values obtainedwithout
an inhibitor (100% binding).
CrystallizationandSolvingtheCFHR14–5Structure—CFHR14–5
was crystallized at 293 K from hanging drops in the presence of
2 M ammonium sulfate and 0.1 M sodium acetate at pH 4.6. The
cube-shaped crystals appeared within 5 days andwere cryopro-
tected with 25% glycerol (supplemented with the mother liq-
uor). The diffraction data (to 2.9 Å) were collected at European
Synchrotron (ESRF) beamline ID14-4 (34) at 100Kon anADSC
Q315r charge-coupled device detector at 0.979520 Å. The data
were indexed and scaled using XDS (35). The structure of
CFH19–20 mutant R1203A (Protein Data Bank code 3KZJ (28))
was used as a searchmodel in Phaser (36), and twomolecules of
CFHR14–5were identified in the asymmetric unit. After succes-
sive rounds of model building with Coot (37) and refinement
using phenix.refine software (38), we could refine the structure
to Rwork/Rfree  0.20/0.26 (see Table 2). The last refinement
cycles were done using TLS parameters (10 TLS groups). In the
Ramachandran plot, 95% of the amino acid structures were
within the most favored region.
The superpositions of different structures and structural
illustrations were prepared using PyMOL software (Schrö-
dinger, Portland, OR). The surface charge distribution of both
the CFHR14–5 and CFH19–20 molecules was calculated using
APBS (39), and the potentials on the solvent-accessible surfaces
were displayed in PyMOL.
Statistical Analyses—Values are expressed as means  S.E.
using GraphPad Prism software (version 6). All curves and bar
diagrams were made using the same software.
RESULTS
Mapping the Autoantibody-binding Residues on CFH19–20—
The binding of IgG from sera of 17 aHUS patients with CFH-
AAs to 14 different CFH19–20mutants was tested (Fig. 2A). The
binding data indicated a congruent tendency as follows. The
binding of IgG from all patients to the L1189R mutant was
diminished by at least 30% compared with WT CFH19–20. IgG
from 14 patients showed at least 30% impaired binding to the
E1198A mutant, and IgG from 10 or 11 patients showed
impaired binding to CFH19–20 mutants T1184R, K1186A, and
K1188A compared withWT CFH19–20 (Fig. 2B). IgG from one
to three patients showed impaired binding tomutants D1119G,
Q1139A, R1182A,W1183L, and R1210A, whereas IgG from all
patients showed similar binding toWTCFH19–20 and mutants
W1157L, R1203A, R1206A, and R1215Q (Fig. 2B).
We also found that binding of mAb C18, which has previ-
ously been shown to have an epitope overlapping with that of
several CFH-AAs (11, 23), to the K1186A mutant was dimin-
ished (Fig. 2A). This antibody efficiently inhibited binding of
CFH-AA to CFH19–20. This inhibition was also observed in
those cases (patients 10, 11, 12, and 14) where the autoanti-
bodies showed only moderately impaired binding to the five
CFH mutants within the common autoantibody binding site
(data not shown). This indicates that the main binding site of
the autoantibodies from those patients is likely to be
overlapping.
The Autoantibody-binding Site Overlaps with the Heparin-
and Common Microbe-binding Sites—Our previously solved
crystal structure of CFH19–20 (7) was used to visualize the loca-
tion of the five residues of CFH19–20 (Thr-1184, Lys-1186, Lys-
1188, Leu-1189, and Glu-1198) that were found to be involved
in binding of CFH-AAs from at least 10 of 17 patients. These
residues form a tightly packed cluster (diameter of 11 Å) on
one side of CFH domain 20 termed the CFH-AA site (Fig. 2C).
Compared with the previously described functional sites on
CFH19–20, theCFH-AA site is clearly distinct from the two sites
for C3b orC3d on domains 19 and 20 (6, 21) but adjacent to and
partially overlappingwith the site involved in binding of CFH to
heparin and endothelial cells (Fig. 2D) (5, 40), as well as with the
recently described common microbe-binding site on CFH
domain 20 (Fig. 2E) (29, 30).
Binding of CFH-AAs to the CFHR1CTerminus—On the basis
of the previously solved structure of CFH19–20, the two residues
that are different in CFH19–20 and CFHR14–5 (Ser-1191 and
Val-1197 of CFH) are buried beneath the identified CFH-AA
site. Therefore, we studied whether the difference of the two
amino acids in the C-terminal domains of CFH and CFHR1 has
an influence on the binding of autoantibodies frompatient sera.
The level of binding of antibodies from patient sera to both
CFH19–20 and CFHR14–5 varied from patient to patient, and
this seemed to correlate to the antibody titer in the sera (Table
TABLE 1
CFH-AA-positive patient sample data
AU, arbitrary units.
Patient
CFHR1
genotype
Sampling
times Ig subtype
Light
chain
type
CFH-AA
titer
AU
Patient 1 / Convalescence IgG3  456
Patient 2 / Convalescence IgG1, IgG3  868
Patient 3 / Acute phase IgG1, IgG3  1325
Patient 4 / Convalescence IgG3  1067
Patient 5 / Acute phase IgG1, IgG3  1043
Patient 6 / Acute phase IgG3  1136
Patient 7 / Convalescence IgG3  1132
Patient 8 / Convalescence IgG3  883
Patient 9 / Convalescence IgG1  1063
Patient 10 / Convalescence IgG3  769
Patient 11 / Acute phase IgG3  3548
Patient 12 / Convalescence IgG1, IgG3  1239
Patient 13 / Acute phase IgG1, IgG3 ,  1260
Patient 14 / Convalescence IgG3  737
Patient 15 / Convalescence IgG3  444
Patient 16 / Convalescence IgG1, IgG3 ,  671
Patient 17 / Convalescence IgG3  852
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1). IgG from 8 of the 10 CFH-AA patient samples of which we
had enough available for analysis bound similarly to CFHR14–5,
CFH, and CFH19–20, whereas binding of autoantibodies from
two of the samples (patients 2 and 9) to CFHR14–5 was dimin-
ished (Fig. 3,A–C). Next, a purified IgG fraction frompatient 11
was used to compare the affinities of CFH-AAs to CFH19–20
and CFHR14–5 by inhibition assay. Binding of IgG to CFH was
somewhat stronger in this assay (Fig. 3, D and E), although a
clear difference in binding to CFH19–20 and CFHR14–5 could
not be detected in the ELISA assay (Fig. 3, B and C). Taken
together, the results on the difference in binding ofCFH-AAs to
CFH19–20 and CFHR14–5 indicated that the conformation of
the CFH-AA site needs to be slightly different in CFH domain
20 and CFHR domain 5.
Structures of the C Termini of CFHR1 and CFH Are Nearly
Identical—To detect possible differences in the CFH-AA site
on CFH19–20 and the corresponding site on CFHR1, we used
x-ray crystallography to solve the structure of CFHR14–5. The
structurewas obtained as a homodimer at 2.9Å resolution from
a different space group (P622) than the previously published
CFH19–20 structures (I4122) (Table 2) (7, 28), but the structures
aligned very well with each other (Fig. 4A). Superimposing the
CFHR14–5 structure with the previously published structures
of CFH19–20 solved as homotetramers (7), in complex with C3d
(6), or in complex with the borrelial OspE protein (29) gave a
root mean square deviation (r.m.s.d.) of 0.5–1.1 Å for the 113
aligned C atoms, indicating that the structures are nearly
identical. Also, the charge potentials on the solvent-accessible
FIGURE 3. Binding of autoantibodies from autoimmune aHUS patients to CFH and CFHR1. A, binding of autoantibodies to CFH (full-length) and its
fragments CFH1–7, CFH8–14, CFH15–20, and CFH19–20. B, binding of IgG autoantibodies to CFH, CFHR1 (full-length), CFHR14–5, and CFHR4B (full-length). Human
serumalbumin (HSA) and/or normal human serum (NHS) was used as a negative control, and goat anti-CFHpolyclonal antibodywas used as a positive control.
C, bar diagram elucidating the relative binding ratio of the patient autoantibodies to CFH19–20 and CFHR14–5. Error bars indicate S.E. The CFHR1 deficiency of
each patient is shown below.D, the binding of purified IgG frompatient 11 to CFH19–20 was tested in the presence of increasing concentrations of CFH19–20 or
CFHR14–5. CFH5–7 was used as a negative control. E, bar diagramof the concentration of CFH19–20 or CFHR14–5 needed for 50% inhibition (IC50) obtained from
three independent experiments performed in triplicates. F, binding of anti-CFH polyclonal antibody to the CFH19–20 mutants. G, no binding was noticed
between CFH19–20 mutants and IgG from normal human serum. Error bars indicate S.E.
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surface displayed at the 2 kT/e level on CFHR14–5 and
CFH19–20 were similar all around the molecules (Fig. 4B).
Differences Noticed in the Structure of the CFH-AA Site of
CFH19–20 and CFHR14–5—The structures of CFH19–20 and
CFHR14–5 are seemingly identical, but the detailed tertiary
structure of the buried region containing mutations S1191L
and V1197A is naturally somewhat different (Fig. 4C). In addi-
tion, as expected on the basis of the differences observed in
binding of certain autoantibodies and the previously reported
functional differences of CFH/CFHR1 hybrid proteins, also the
conformation of the CFH-AA site on CFHR14–5 is slightly dif-
ferent from that onCFH19–20 (r.m.s.d. of the backbone atoms of
the loop region  3 Å). Both the backbone and loops forming
the CFH-AA site (Arg-281–Leu-288 of CFHR1 and Arg-1182–
Leu-1189 of CFH, respectively) have a different orientation
(Fig. 4D). Themain difference in the backbone is the formation
of a short -helix in the loop of CFHR14–5, whereas no promi-
nent helix is seen in this region in any of the solved structures of
CFH19–20. The orientation of some of the side chains is also
clearly different, as Arg-281–Leu-288 of CFHR14–5 are distinc-
tively apart from the location of the side chains of the corre-
sponding residues of CFH19–20 (Arg-1182–Leu-1189) (Fig.
4D). Also, the hydrogen bonds stabilizing the loop in CFH and
CFHR1 are clearly different (Fig. 4, E and F). The real space
correlation coefficients and the B-factors of the loop residues
show normal behavior (Fig. 4G), and there are no crystal con-
tacts within this region in either the CFHR14–5 or CFH19–20
structure. Interestingly, only one of the two CFHR14–5 mole-
cules in the same crystalline space shows a conformation that is
dissimilar to the CFH-AA site on CFH domain 20, whereas the
other CFHR14–5 molecule has a site that is similar to CFH.
Because the data indicated that theArg-281–Leu-288 loop of
CFHR1 is flexible (or has two conformations), we next analyzed
whether flexibility is observed in the CFH-AA site of the previ-
ously published structures of CFH19–20. The conformation of
the Arg-1182–Leu-1189 loop is somewhat different in free
CFH19–20 compared with themutually similar conformation of
CFH19–20 in complex with either the microbial protein OspE
(r.m.s.d. of the backbone of the loop residues  2.7 Å) or the
natural ligands C3d (r.m.s.d. of the backbone of the loop resi-
dues  3.0 Å) or sialic acid glycan (r.m.s.d. of the backbone of
the loop residues 2.9 Å) (Fig. 4H). This conformation is also
different from that of CFHR1 (r.m.s.d. of the backbone of the
loop residues  3.0 Å). This indicates the structural flexibility
of the CFH-AA site upon binding of a ligand to the same
domain (Fig. 4H).
To exclude potential misinterpretation of the x-ray diffrac-
tion data of the CFH-AA site, we next compared the electron
density maps (2mFo  DFc) of Arg-1182–Leu-1189 of
CFH19–20 (7) and Arg-281–Leu-288 of CFHR14–5 (Fig. 5).
Clearly, the model of CFHR14–5 (but not CFH19–20) fits very
well with the electron density map of CFHR14–5 in this region
(Fig. 5, A and B), whereas the corresponding region in the
model of CFH19–20 (but not CFHR14–5) fits well with the elec-
tron density map of CFH19–20 (Fig. 5, C and D).
DISCUSSION
Autoimmune aHUS is an unusual autoimmune disease
because it is associated with a deficiency of a protein (CFHR1)
homologous to the autoantigen (CFH). Therefore, it offers an
exceptional opportunity to study phenomena leading to anti-
body-associated autoimmunity. This study shows that the
amino acid residues contributing to the binding sites of CFH-
AAs from17patientswith autoimmune aHUS forma cluster on
domain 20 of CFH adjacent to the common microbe-binding
site. The differential binding of CFH-AAs from two aHUS
patients to CFH19–20 and CFHR14–5, as also suggested previ-
ously (13, 26), and the small but clear differences in the x-ray
crystal structures of the loop forming the autoantigenic epitope
on CFH and CFHR1 indicate that the C-terminal domain of
CFH and CFHR1 can have slightly different conformations. In
addition, the conformation of the autoantigenic loop on CFH
seems flexible becausewe noticed that the loop conformation is
slightly different after binding of ligands to domain 20 of CFH
in the previously published structures (22, 29). The reason for
the association of CFHR1 deficiency with aHUS is unexplained,
but our results enabled us to evaluate previous results and
explanation models and to generate a new hypothesis of an
induced autoantigenic neoepitope. This explains the associa-
tion between CFHR1 deficiency and autoantibody formation
against the common CFH-AA epitope on domain 20.
aHUS-associated mutations in the C-terminal domains of
CFH have been shown to cause reduced binding of CFH to C3b
or host cell-surface structures such as glycosaminoglycans/
heparin (5–7, 41–43). aHUS-associated autoantibodies to
CFH19–20 cause uncontrolled complement attack against host
cells, and autoantibodies from some patients have been shown
to impair CFH binding to C3b or to host cells (11). The location
of the CFH-AA-binding site we identified on domain 20 indi-
cates that the autoantibodies are likely to block binding of CFH
at least to glycosaminoglycans/heparin due to the proximity of
the CFH-AA site to the heparin-binding site. In addition, the
location of the hemolysis-inducing aHUS mutation W1183L
(26, 44) next to the CFH-AA site (Figs. 2C and 4D) indicates the
importance of the site in protecting host cells from comple-
TABLE 2
Data collection and refinement statistics for CFHR14–5
Statistics for the highest resolution shell are shown in parentheses.
Resolution range (Å) 48.53–2.897 (3.001–2.897)
Space group P622
Unit cell dimensions
a, b, c (Å) 143.406, 143.406, 77.784
, ,  90°, 90°, 120°
Unique reflections 10,935 (1048)
Completeness (%) 99.78 (98.59)
Mean I/I 15.30 (2.46)
Wilson B-factor 72.41
Rwork 0.2070 (0.3078)
Rfree 0.2683 (0.3642)
No. of atoms 1939
Macromolecules 1904
Ligands 35
Water 3
Protein residues 248 (both molecules in the asymmetric unit)
r.m.s.d.
Bond lengths (Å) 0.009
Bond angles 1.16°
Ramachandran favored (%) 95
Ramachandran outliers (%) 0
Average B-factor 96.4
Macromolecules 95.5
Solvent 80.4
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FIGURE 4.Crystal structure of CFHR14–5 and comparisonwith the previously solved structure of CFH19–20. A, structural superposition of the twomolecules of
CFHR14–5 (orange and yellow) found in the asymmetric unit along with CFH19–20 (gray) shown in a cartoon representation. B, comparison of the surface charge
potentials of CFHR14–5 and CFH19–20. Potentials on the solvent-accessible surfaces were calculated and displayed at the 2 kT/e level on both structures after
modelingallof themissingsidechainsof thepreviouslypublishedstructureofCFH19–20 (ProteinDataBankcode2G7I) (7).C, close-upviewof the tworesidues thatare
different in the amino acid sequences of these two protein constructs with the 2mFoDFc electron densitymap of CFHR14–5 shown.D, close-up view of the region
inwhich the tertiary structures of CFHR14–5 andCFH19–20 are dissimilar (Arg-1182–Leu-1189of CFH19–20 and the correspondingArg-281–Leu-288of CFHR14–5)with
backbone and side chain atoms shown as a stick model. This region corresponds to the CFH-AA-binding site shown in Fig. 2C. The hydrogen bonds found in the
autoantigenic loop of CFH (E) and its homologous region in CFHR1 (F) that stabilize the structure.G, comparison of the real space correlation constants and B-factors
of the residues of CFHR14–5. The B-factors are indicated on the right y axis, and the real space correlation coefficients are indicated on the left y axis. The CFH-AA site
(Arg-281–Leu-288) is indicated.H,cartoonrepresentationof thestructural superpositionofCFHR14–5 (orange; ProteinDataBankcode4MUC)withCFH19–20 (gray; code
2G7I (7)), CFH19–20 in complexwith a sialic acid glycan and C3d (slate; code 4ONT (22)), and CFH19–20 in complexwithOspE (turquoise; code 4J38 (29)).
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ment. Although both the C3b-binding sites on CFH19–20, one
on domain 19 and the other on domain 20 (6, 21), are relatively
distant from the CFH-AA-binding site, the CFH-AAs might
interfere with C3b binding due to their large size, as has been
reportedwithmAbC18, whichwe now (Fig. 2A) and previously
found (11) to bind to the same region as the CFH-AAs. Dimin-
ished binding of CFH to either the cell-surface structures or
C3b can lead to compromised protection of the plasma-ex-
posed host cells, which has been reported widely in aHUS
patients (1).
Close comparison of the conformation of the autoantigenic
loop of CFH in the published crystal and NMR structures of
CFH19–20 (6, 7, 21, 22, 29, 40, 45) showsminor differences in the
Arg-1182–Leu-1189 region of CFH19–20 in complex withOspE
(29), C3d (6), or a sialic acid glycan (22). The r.m.s.d. of the
backbone atoms of the loop region is 2.7–3.0 Å compared with
CFH19–20 alone (Fig. 4H). Binding of CFH19–20 to heparin
tetrasaccharide has also been shown to cause chemical shift
perturbations in NMR at the CFH-AA site (22, 40). Thus, it is
likely that the conformation of the region is somewhat flexible.
It seems possible that the corresponding site on CFHR1 is also
structurally flexible because of the two monomers in the unit
cell of the CFHR14–5 crystal lattice, conformation of the
CFH-AA site of one monomer was similar to CFH, and the
other one was different (Fig. 4A). The key difference between
CFHandCFHR1 could therefore be thatCFHR1 takes the alter-
native conformation spontaneously, whereas on the basis of
various crystal and NMR structures, CFH19–20 takes a slightly
altered conformation only upon binding of a ligand. However,
we do not suggest that binding of self-molecules (such as hep-
arin, C3b, or sialic acids) leads to autoimmunity, but the flexi-
bility of the autoantigenic loop upon binding of these ligands to
CFH domain 20 is obvious.
The observed difference between the CFHR14–5 and the
CFH19–20 structures is unlikely to be a crystallographic artifact
due to the four following reasons. First, only one of the mono-
mers in the unit cell containing two CFHR14–5 molecules
shows a structure that is considerably different from CFH
domain 20 (see Protein Data Bank code 4MUC), indicating
structural flexibility in that loop of CFHR1 domain 5. Second,
there are no direct contacts between the residues of the
CFH-AA site (Arg-281–Leu-288) and the molecule in the
neighboring crystal cell. Third, CFH-AAs from two of the stud-
ied 10 patients bound differently to CFH19–20 and CFHR4–5
(Fig. 3C), indicating that there is a difference within the CFH-
AA-binding site of these molecules. Fourth, CFHR14–5 and
CFH19–20 have been reported to have functional differences
(45), which is obvious because the fusion proteins CFH1–18/
CFHR14–5 and CFHR11–3/CFH19–20 are associated with aHUS
and have different functions compared with normal full-length
CFH and CFHR1 (4, 18–20). Because domain 19 of CFH and
domain 4 of CFHR1 are identical, it has been deduced that the
difference leading to the clinical disease is within the terminal
domain of the fusion proteins, leading to the inability to control
complement on self-surfaces (19). Our results suggest that the
reason for the functional difference between themost C-termi-
nal domains of CFH andCFHR1 is their varied ability to bind to
heparin or glycosaminoglycans on self-cells because the loop
that has a different conformation in CFH and CFHR1 contains
several of the heparin-binding residues (Fig. 2,C andD; and Fig.
4D) (5, 40).
Nearly all patients with CFH-AAs lack CFHR1 (12, 13); thus,
it is likely that the absence of CFHR1 imparts the risk of
CFH-AA generation. The risk for anti-CFH autoimmunity in
the absence of CFHR1 is very high, as the odds ratio is 442 (16).
In this study, we provided data for a structure-based molecular
explanation of the phenomenon. The explanation is based on
four observations from our study. First, the binding sites of
CFH-AAs from the 17 patients analyzed clearly formed a clus-
ter, the CFH-AA site. Second, the CFH-AA site in CFH
A B 
C D 
FIGURE 5. Comparison of the models and 2mFo DFc electron density maps of the CFH-AA-binding site of CFH19–20 and the corresponding site of
CFHR14–5. The CFHR14–5 loop region (Arg-281–Leu-288; A) and the CFH19–20 loop region (Arg-1182–Leu-1189; B) are shown with the CFHR14–5 2mFo DFc
electrondensitymap. TheCFH19–20 loop region (Arg-1182–Leu-1189;C) and theCFHR14–5 loop region (Arg-281–Leu-288;D) are shownwith theCFH19–20 2mFo
 DFc electron density map. A stick model and electron density map of CFHR14–5 are displayed in orange, and those of CFH19–20 in gray.
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domain 20 is adjacent to the two buried residues (Ser-1191
and Val-1197) that are different between CFH19–20 and
CFHR14–5. Third, although the crystal structures of
CFHR14–5 and CFH19–20 are similar due to the 98.5%
sequence identity between them, there is a small structural
difference exactly at the CFH-AA site on the Arg-1182–Leu-
1189 loop of CFH (Fig. 4D). Fourth, a small conformational
change has been detected within the autoantigenic loop
upon binding of CFH19–20 to a microbial protein (29), a sialic
acid glycan (22), heparin, or C3d.
The two usual models to explain autoantibodies in general,
an analogous epitope (molecular mimicry) (46) and a
co-epitope (formed by adjacent molecules) (47), are unable to
explain the association between CFHR1 deficiency and
CFH-AA binding to the CFH-AA site on domain 20. Thus, on
the basis of the newdata, we propose a novel explanation for the
association of CFHR1 deficiency with the autoimmune disease.
In this model, called the “induced neoepitope model,” the nor-
mal structure of the Arg-1182–Leu-1189 loop of CFH can be
turned into an autoantigenic conformation upon induction by
at least one microbial ligand binding to that region of CFH
domain 20 (Fig. 6). It has been reported that several kinds of
infections can precede autoimmune aHUS, and this is concord-
ant with our model because several microbial molecules are
known to bind close to the autoantigenic epitope of CFH (29,
30), and we observed from previously published data that
CFH19–20 in complex with OspE (29) has a slightly altered con-
formation in this region.
It is possible that binding of certain microbial ligands to the
autoantigenic loop or close to it leads to masking of the autoanti-
genic epitope.We reported previously that several microbes bind
next to the autoantigenic loop (30). Therefore, all of these may
induce the autoantigenic neoepitope, but some of them could
simultaneously mask the loop. This is the case at least with borre-
lial OspE, which binds directly to the autoantigenic loop (29). It is
noteworthy that borreliosis has never been reported preceding
autoimmune aHUS. Therefore, we do not suggest that all micro-
bial molecules that bind to CFH domain 20 could lead to autoim-
munity in CFHR1-deficient individuals. However, it is possible
that some of the microbial molecules that bind to the domain do
not mask the autoantigenic loop, thereby leading to the risk of
autoimmunity in the absence of CFHR1 (Fig. 6).
Our model provides an explanation as to why immunization
against the CFH-AA site could occur only in CFHR1-deficient
Normal individual 
CFHR14 
CFHR15 
CFH19 
CFH20 
CFH CFHR1 
 laudividni tneicifed 1RHFC
CFHR14 
CFHR15 
CFH19 
CFH CFHR1 
CFH20 
Infection 
CFH20 
CFHR14 
CFHR15 
CFH19 
CFH CFHR1 
CFH20 
CFH19 
CFH 
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Induced 
neoepitope 
Microbial protein 
OR 
CFH20 
CFH19 
CFH 
Induced 
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Microbial protein 
OR 
CFH20 
CFHR14 
CFHR15 
CFH19 
CFH CFHR1 
Microbial protein induces 
an unmasked neoepitope, 
but the presence of CFHR1 
has led to tolerance to such 
a neoepitope. 
Microbial protein (eg. 
borrelial OspE) 
induces neoepitope, 
but simultaneously 
masks it from B cells. 
Microbial protein 
induces neoepitope 
without masking it; 
no tolerance due to 
CFHR1 deficiency. 
CFH-autoantibodies No CFH-
autoantibodies 
No CFH-
autoantibodies 
AI-aHUS 
FIGURE 6. Schematic illustration of a model to explain the occurrence of CFH-AAs in aHUS, with special attention to the strong association of
autoimmune aHUS with homozygous deficiency of CFHR1. Upper panels, the phenotypes of normal and CFHR1-deficient individuals are shown
schematically to indicate the structural difference observed between the CFH-AA site and the corresponding site on CFHR1 (dark gray protrusion). In the
novel “induced neoepitope model,” binding of a microbial protein to CFH domain 20 (adjacent to the autoantigenic Arg-1182–Leu-1189 loop, thus not
masking it from B-cells) induces a conformational change in the Arg-1182–Leu-1189 loop of domain 20, thereby making its conformation similar to that
of CFHR1 domain 5.
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individuals because, in normal individuals, the presence of
CFHR1 with an epitope similar to the hypothetical induced
autoantigenic conformation of CFH would have guaranteed
tolerance to that conformation of CFH. The model proposed
here also explains the other four key biological phenomena
described in autoimmune aHUS. First, the association with
infections (14, 48). Second, the clustering of the autoantibody
epitopes on CFH domain 20 (Fig. 2). Third, the high prevalence
of IgG or IgA class autoantibodies (9, 26) because the foreign
peptide needed for class switch of B-cells byT-cell help could be
provided by the microbial protein bound to CFH19–20. And
finally, themodel explains the polyclonality of the autoimmune
response (15) because different epitopes on the autoantigenic
loop could be recognized by various B-cell receptors.
In this study, we have shown that CFH-AAs bind to a com-
mon site on the Arg-1182–Leu-1189 loop of CFH next to the
two buried residues that are different in CFH19–20 and
CFHR14–5. The crystal structure of CFHR14–5 presented here
shows that the conformation of the autoantigenic loop is differ-
ent in CFH and CFHR1. Taken together, these data provided
the basis for the suggested novel model (Fig. 6) to explain how
CFHR1 deficiency is linked to CFH-AA formation.
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